Clinical Trials
57 trialsNCT07510334 2026-06-05
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Recruiting
NCT03866382 2026-06-03
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04981509 2026-06-03
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05155033 2026-05-29
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT07023432 2026-05-22
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06053658 2026-05-20
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06863311 2026-05-18
EXACT
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT06940518 2026-05-15
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06708949 2026-05-14
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06852638 2026-05-12
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Phase 2 Recruiting
NCT07571551 2026-05-11
TRIPLE-PATH
Jinling Hospital, China
Phase 2 Recruiting
NCT05363280 2026-05-08
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Advenchen Laboratories, LLC
Phase 2 Recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07188896 2026-05-01
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05361720 2026-04-27
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06376669 2026-04-03
SPARE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03786796 2026-03-30
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06699602 2026-03-04
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07223541 2026-03-02
LAG-BOOST
University of Oklahoma
Phase 2 Recruiting
NCT05641935 2026-02-17
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
Thomas Jefferson University
Phase 2 Recruiting
NCT07389629 2026-02-05
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT07386158 2026-02-04
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT07077161 2026-01-28
SKIPPY 2
Leiden University Medical Center
Phase 2 Recruiting
NCT04299646 2026-01-13
GETUG-StORM-01
Centre Francois Baclesse
Phase 2 Recruiting
NCT05830058 2026-01-05
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT07187778 2026-01-05
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06680089 2025-12-31
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Phase 2 Recruiting
NCT04974671 2025-12-04
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Yale University
Phase 2 Recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT06601296 2025-11-12
SPARK
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT06005818 2025-10-21
MRD GATE RCC
University of Alabama at Birmingham
Phase 2 Recruiting
NCT05931393 2025-10-10
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT07175480 2025-09-16
Perfumer
Jinling Hospital, China
Phase 2 Recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT06302569 2025-09-09
REPRINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Recruiting
NCT06255223 2025-09-03
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
Phase 2 Recruiting
NCT05319015 2025-08-22
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT06642220 2025-07-20
ARRCC
Western University, Canada
Phase 2 Recruiting
NCT06447103 2025-06-12
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05127824 2025-05-04
Autologous Dendritic Cell Vaccine in Kidney Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT06281678 2024-12-19
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Recruiting